

## PRODUCT

Therapeutic antibodies targeting complement

## INDICATION

Multiple potential indications related to complement targets, including multiple rare diseases

## VALUE PROPOSITION

- Platform opportunity with multiple therapeutic targets
- Potential for accelerated development and regulatory pathways
- Experienced biologic therapeutic development team

## DEVELOPMENT STAGE

Most advanced asset in portfolio is humanized and preparing for IND-enabling studies

## INTELLECTUAL PROPERTY

Provisional patent applications filed

## RELATED PUBLICATIONS

Lin K, ... **Lin F**. Blood Adv. 2020 May 12;4(9):2049-2057.  
[PMID: 32396613](#).

Chen JY, ... **Lin F**. Clin Immunol. 2023 Jun 12;253:109678.  
[PMID: 37315680](#).

## CONTACT INFORMATION

Joe Barone  
Director, Business Development  
Cleveland Clinic Innovations  
[baronej2@ccf.org](mailto:baronej2@ccf.org)  
631.278.5858

# Antibody-Based Complement Inhibitor Platform


*Feng Lin, PhD – Cleveland Clinic Lerner Research Institute*

## OPPORTUNITY

- The complement system comprises a group of over 50 proteins that augment immune responses
- Complement is implicated in a wide range of diseases and has emerged as a target for new therapeutics

## SOLUTION

- Feng Lin, PhD, a world leader in the complement biology field, has developed a pipeline of antibody therapies target different proteins in the complement cascade.
- The pipeline's most advanced assets, anti-C6 and anti-C2 therapies, each demonstrated efficacy in complement humanized mouse models
- Potential indications include age-related macular degeneration, myasthenia gravis, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, autoimmune hemolytic anemia, catastrophic antiphospholipid syndrome, Guillain Barre syndrome, sickle cell disease, and others...



**Lin Laboratory pipeline of complement-targeting therapeutics in development**